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Abstract
Coronary artery disease (CAD) has a significant genetic contribution that is incompletely characterized. To complement
genome-wide association (GWA) studies, we conducted a large and systematic candidate gene study of CAD susceptibility,
including analysis of many uncommon and functional variants. We examined 49,094 genetic variants in ,2,100 genes of
cardiovascular relevance, using a customised gene array in 15,596 CAD cases and 34,992 controls (11,202 cases and 30,733
controls of European descent; 4,394 cases and 4,259 controls of South Asian origin). We attempted to replicate putative
novel associations in an additional 17,121 CAD cases and 40,473 controls. Potential mechanisms through which the novel
variants could affect CAD risk were explored through association tests with vascular risk factors and gene expression. We
confirmed associations of several previously known CAD susceptibility loci (eg, 9p21.3:p,10
233; LPA:p,10
219;
1p13.3:p,10
217) as well as three recently discovered loci (COL4A1/COL4A2, ZC3HC1, CYP17A1:p,5610
27). However, we
found essentially null results for most previously suggested CAD candidate genes. In our replication study of 24 promising
common variants, we identified novel associations of variants in or near LIPA, IL5, TRIB1, and ABCG5/ABCG8, with per-allele
odds ratios for CAD risk with each of the novel variants ranging from 1.06–1.09. Associations with variants at LIPA, TRIB1, and
ABCG5/ABCG8 were supported by gene expression data or effects on lipid levels. Apart from the previously reported variants
in LPA, none of the other ,4,500 low frequency and functional variants showed a strong effect. Associations in South Asians
did not differ appreciably from those in Europeans, except for 9p21.3 (per-allele odds ratio: 1.14 versus 1.27 respectively; P
for heterogeneity=0.003). This large-scale gene-centric analysis has identified several novel genes for CAD that relate to
diverse biochemical and cellular functions and clarified the literature with regard to many previously suggested genes.
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Introduction
Coronary artery disease (CAD) has a substantial genetic
component which is incompletely characterised. Genomewide
association (GWA) studies have recently identified several novel
susceptibility loci for CAD [1–9]. Because GWA studies involve
assumption-free surveys of common genetic variation across the
genome, they can identify genetic regions responsible for previously
unsuspected or unknown disease mechanisms. However, despite the
success of the GWA approach, it has potential limitations. Because
CAD loci identified through GWA studies have predominantly
been found in regions of uncertain biological relevance, further
work is required to determine their precise contribution to disease
aetiology. Furthermore, in contrast with their high coverage of
common genetic variation, GWA studies tend to provide limited
coverage of genes with well-characterised biological relevance
(‘‘candidate genes’’) [2], particularly in relation to lower frequency
genetic variants (such as those with minor allele frequencies of 1–
5%). Such variants are also often difficult to impute from GWA
data. Although candidate gene studies should provide more
comprehensive coverage of lower frequency and functional variants
than GWA studies, most have been inadequately powered.
To complement GWA studies, we undertook a large-scale gene-
centric analysis of CAD using a customised gene array enriched
with common and low frequency variants in ,2,100 candidate
cardiovascular genes reflecting a wide variety of biological pathways
[10]. The array’s potential to identify disease-associated lower
frequencyvariantshasbeen demonstratedbypreviousidentification
of strong independent associations with 2 variants in the LPA gene -
rs3798220 (minor allele frequency 2%), and rs10455872 (7%) - and
CAD risk [11]. We have now investigated this gene array in a
further 13 studies comprising a total of 15,596 CAD cases and
34,992 controls. To enable interethnic comparisons, participants
included 4,394 cases and 4,259 controls of South Asian descent, an
ethnicgroup withhighsusceptibility to CAD. Forfurtherevaluation
of putative novel associations, we attempted to replicate them in an
additional 17,121 cases and 40,473 controls.
Results
The experimental strategy used is shown in Figure 1. In the
discovery phase we genotyped participants from 12 association
studies of CAD/myocardial infarction (MI), including a total of
11,202 cases and 30,733 controls of European descent (10 studies),
plus 4,394 South Asian cases and 4,259 South Asian controls (2
studies) (Table 1, Table S1, with further details of the studies given
in Text S1).
Associations with known CAD loci
36,799 SNPs passed QC and frequency checks and were
included in the meta-analysis (reasons for exclusion of variants in
each study are given in Table S2). The distribution of association P
values in the discovery stage analyses are shown in Figure 2. We
found significant associations with CAD for several previous
GWA-identified loci contained on the array including 9p21.3
(rs1333042, combined European and South Asian P=1.1610
237)
and 1p13.3 (rs646776, 3.1610
217; Table S3). We also confirmed
associations of other genes with strong prior evidence including
the first association of a variant at the apolipoprotein E
locus at genomewide significance (APOE/TOMM40, rs2075650,
P=3.2610
28), as well as associations at apolipoprotein (a) (LPA,
rs10455872, P=1.2610
220), and low density lipoprotein receptor
(LDLR, rs6511720, P=1.1610
28; Table S3). However, we found
no persuasive evidence of association of several prominently-
studied genes and variants for which the previous epidemiological
evidence has been inconclusive, even though the majority of these
loci were well-tagged (Table S4) and the current study was well-
powered to detect associations of modest effect (Figure S1).
Notable variants that did not show significant association included
the angiotensin converting enzyme (ACE) insertion/deletion
polymorphism, the cholesteryl-ester transfer protein (CETP) Taq1B
polymorphism and the paraoxonase 1 (PON1) Q192R polymor-
phism (Table S4). Perhaps contrary to expectation, apart from the
LPA variant rs3798220, we did not observe any other strong
association (odds ratio .1.5) among the ,4,500 low frequency (1–
5%) variants and/or variants with suspected or known functional
impact on protein structure/function or gene expression specifi-
cally selected for the inclusion on the array (Table S3).
Novel CAD loci
Based on simulations conducted prior to the analysis (Figure
S2), loci were eligible for replication if unadjusted P-values for
CAD were ,1610
24 in either the primary (each ethnic group
analysed separately) or secondary (combined) analyses and the loci
had not been previously established with CAD. This identified 27
loci in total: 15 in the European only analysis, 3 in the South
Asian only analysis, and 9 in the combined analysis (Table S5). A
recent GWA meta-analysis from the CARDIoGRAM Consor-
tium with some overlapping cohorts to those in our study, reports
discovery of three of these loci [12]: COL4A1/COL4A2, ZC3HC1,
CYP17A1. The P values observed for the lead variants at these
loci in the current study were: COL4A1/COL4A2: rs4773144,
P=3.5610
28; ZC3HC1: rs11556924, P=3.1610
27; CYP17A1:
rs3824755, P=1.2610
27, providing further strong evidence for
the association of these loci with CAD. Hence, only the lead
SNPs at the 24 remaining loci were taken forward for replication.
This was done in silico in 17,121 CAD cases and 40,473 controls,
all of whom were of white European ancestry and derived from
non-overlapping cohorts from CARDIoGRAM and EPIC-NL
(Text S1, Table S6). The power of our replication sample to
confirm significant associations is shown in Figure S1. Of the 24
variants taken forward, four were independently replicated (1-
tailed Bonferroni-corrected P,0.05 is P,1.9610
23; Figure 3,
Table S5), comprising variants in or adjacent to: LIPA, IL5,
TRIB1 and ABCG5/ABCG8 (Figure 4). For the variant at the
LIPA locus, the combined P-value was 4.3610
29,e x c e e d i n g
conventional thresholds for GWA studies. For each of the IL5,
TRIB1 and ABCG5/ABCG8 variants, the P-value was ,3610
26,
exceeding array-wide levels of significance (Figure 3). CAD
associations in the individual component studies are shown in
Figure S3. The CAD associations for these loci did not vary
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(Figure S4).
Potential mechanisms
To investigate whether the 4 newly identified loci associate with
cardiovascular risk traits, we interrogated available data from
previous GWA meta-analyses of diabetes mellitus (n=10,128
individuals) [13], systolic blood pressure (n=25,870) [14], and
low-density (LDL) and high-density (HDL) lipoprotein-cholesterol
and triglycerides (n=99,900) [15]. This showed that the risk allele
at the TRIB1 locus was associated with higher triglyceride
(P=3.2610
253), higher LDL-C (P=6.7610
229) and lower
HDL-C (P=9.9610
217) and that the ABCG5/ABCG8 risk allele
was associated with higher LDL-C (P=1.7610
247; Figure 5). We
also examined the association of the novel risk variants with gene
expression in full transcriptomic profiles of circulating monocytes
derived from 363 patients with premature myocardial infarction
and 395 healthy blood donors from the Cardiogenics study (Text S1).
We found a highly significant association (P=1.0610
2124) of the
risk allele at the LIPA locus with LIPA mRNA levels in these cells
explaining ,50% of the variance in the expression of the gene
(Figure 6).There were no other highly significant associations
between CAD risk alleles and gene expression at the novel loci
(Table S7a and S7b).
Ethnic-specific analyses
We explored whether associations of loci with CAD differed
between individuals of white European ancestry and South Asian
ancestry. For most loci, frequency of risk alleles and pattern of risk
associations did not differ qualitatively by ethnicity, although the
evidence of association was often weaker in South Asians, perhaps
due to lower power (Figure 3, Tables S3 and S5). For the 9p21.3
locus, despite similar risk allele frequencies (Table S3), odds ratios
were higher in Europeans than South Asians (rs1333042: 1.27 v
1.14; P=0.003 for difference), though common haplotype
frequencies did not vary by ethnicity (Table S8). The three
variants at the TUB, LCT and MICB loci selected for replication
on the basis of South Asian-specific results did not show evidence
of association in Europeans (Table S5).
Discussion
Our in-depth study of ,2,100 candidate genes has yielded
several novel and potentially important findings, adding to the
emerging knowledge on the genetic determination of CAD. First,
we have identified several novel genes for CAD. These genes relate
to diverse biochemical and cellular functions: LIPA for the locus on
10q23.3; IL5 (5q31.1); ABCG5/ABCG8 (2p21); TRIB1 (8q24.13);
COL4A1/COL4A2 (13q34); Z3HC1 (7q32.3); and CYP17A1
(10q24.3). We have furnished evidence directly implicating the
candidacy of these genes, either because the locations of the signals
discovered are within a narrow window of linkage disequilibrium
or because there is evidence of a mechanistic effect, or both.
Second, we have provided large-scale refutation of the relevance of
many prominent candidate gene hypotheses in CAD, thereby
clarifying the literature. Third, contrary to expectation, we did not
observe highly significant novel associations between low frequen-
cy variants and CAD risk, despite study of .4,500 such variants.
Fourth, we have confirmed the relevance of several previously
established CAD genes to both Europeans and South Asians,
without finding qualitative differences in results by ethnicity.
LIPA (lipase A) encodes a lysosomal acid lipase involved in the
breakdown of cholesteryl esters and triglycerides. Mutations in
LIPA cause Wolman’s disease [16], a rare disorder characterized
by accumulation of these lipids in multiple organs. However,
despite evidence that the risk allele was associated with higher
LIPA gene expression (suggesting that both under- and over-
activity of LIPA increase CAD risk), it was not significantly
associated with altered lipid levels. This finding suggests that the
impact on CAD risk is either through an alternative pathway, or
that the mechanism is more complex than reflected through
conventionally measured plasma lipid levels. Two recent studies
have also found associations of variants in the LIPA gene with
CAD using a GWA approach, strengthening the evidence for this
association [17,18].
Our identification of the association of variants near interleukin
5( IL5), an interleukin produced by T helper-2 cells, is interesting
given the evidence that both acute and chronic inflammation may
play important roles in the development and progression of CAD
[19]. Most previous human association studies of inflammatory
genes and CAD have focused on other cytokines and acute-phase
reactants. Nevertheless, some experimental data predict that IL-5
has an atheroprotective effect and this has been supported by
association between higher circulating IL-5 levels and lower carotid
intimal-medial thickness [20–22]. Our findings now highlight the
potential importanceofIL-5inCAD, especially as the IL-5receptor
isalreadyaviabletherapeutictargetinallergicdiseases,althoughwe
cannot ruleoutthepossibilitythat anothergene atthislocus maybe
mediating the association with CAD risk.
The ATP-binding cassette sub-family G proteins ABCG5 and
ABCG8 are hemi-transporters that limit intestinal absorption and
promote biliary excretion of sterols. Mutations in either gene are
associated with sitosterolaemia, accumulation of dietary cholesterol
and premature atherosclerosis [23]. Recently, common variants in
ABCG8have also been showntobeassociated withcirculatingLDL-
C and altered serum phytosterol levels with concordant changes in
risk of CAD [15,24]. Our findings confirm that this locus affects
CAD risk either directly through its effect on plasma phytosterol
levels or through primary/secondary changes in LDL-cholesterol.
The association signal on 8q24.13 maps near the TRIB1 gene
which encodes the Tribbles homolog 1 protein. Tribbles are a
Author Summary
Coronary artery disease (CAD) has a strong genetic basis
that remains poorly characterised. Using a custom-
designed array, we tested the association with CAD of
almost 50,000 common and low frequency variants in
,2,000 genes of known or suspected cardiovascular
relevance. We genotyped the array in 15,596 CAD cases
and 34,992 controls (11,202 cases and 30,733 controls of
European descent; 4,394 cases and 4,259 controls of South
Asian origin) and attempted to replicate putative novel
associations in an additional 17,121 CAD cases and 40,473
controls. We report the novel association of variants in or
near four genes with CAD and in additional studies identify
potential mechanisms by which some of these novel
variants affect CAD risk. Interestingly, we found that these
variants, as well as the majority of previously reported CAD
variants, have similar associations in Europeans and South
Asians. Contrary to prior expectations, many previously
suggested candidate genes did not show evidence of any
effect on CAD risk, and neither did we identify any novel
low frequency alleles with strong effects amongst the
genes tested. Discovery of novel genes associated with
heart disease may help to further understand the aetiology
of cardiovascular disease and identify new targets for
therapeutic interventions.
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function, although their precise roles are unclear [25]. However,
SNPs in or near TRIB1 - including the lead SNP in our study
(rs17321515) - have recently been shown to have highly
significant associations with levels of several major lipids [15],
providing a possible mechanism for their association with CAD.
Our findings confirm the previous suggestion that this variant is
also associated with CAD risk [15,26]. Hepatic over-expression of
TRIB1 in mice has been shown to lower circulating triglycerides;
conversely, targeted deletion of the TRIB1 gene in mice led to
higher circulating triglycerides [27]. The location of the CAD-
associated variant downstreamof TRIB1 suggests that itseffect may
be mediated by regulation of TRIB1 expression leading to adverse
lipid profiles, although we did not find an eQTL at this locus in
monocytes.
Our study brings to 33 the number of confirmed loci with
common variants affecting risk of CAD (Figure 7). We estimate that
in aggregate these variants explain about 9% of the heritability of
CAD which is consistent with the recent analysis by CARDIo-
GRAM [12]. Interestingly, the odds ratios that we observed for the
novel loci were generally lower than those of previously identified
loci. This suggests that most of the common variants with moderate
effects have been identified and that increasingly larger sample sizes
will be required to detect further common variants that affect risk of
CAD. However, the modest odds ratios associated with such
variants do not necessarily imply that they are not of potential
clinical or therapeutic relevance. For example, there are only
modest effects of common variants in the LDLR gene on CAD risk
(Figure 7); yet this pathway has become a major target for the
prevention and treatment of CAD with the development of statins.
Figure 1. Design of the study.
doi:10.1371/journal.pgen.1002260.g001
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common variants that affect risk of CAD, such loci explain only a
small proportion of the heritability of CAD [5]. It has been
hypothesized that some of the unexplained heritability resides in
lower frequency (1–5%) variants which are not adequately
represented on current genomewide arrays and/or are difficult to
impute from GWA data. Because the gene array used in the current
study included ,4500 lower frequency variants as well as known
functional variants for the majority of the genes on the array, we were
able to examine this issue for CAD, at least in relation to candidate
cardiovascular genes. Although we confirmed the previously reported
associationsoflowerfrequencyvariantsinLPAand PCSK9 with CAD
risk, we did not detect any other strongly associated variants in the 1–
5% range or an enrichment of low frequency variants amongst SNPs
that showed nominal association with CAD. However, it is important
tonotethat rarevariantsinthegenome(minorallelefrequency,1%)
were not addressed in this study.
CAD is more common in South Asians and tends to occur at an
earlier age than in Europeans, perhaps partly due to genetic
factors [28]. Our study provides the first systematic exploration of
this issue. We observed a weaker effect size for the 9p21.3 locus in
South Asians compared with Europeans, although this did not
appear to be related to any obvious differences in haplotype
structure at the locus, confirming recent findings in Pakistanis [29].
This difference in effect size between ethnic groups will require
further evaluation and replication as other differences between the
European and South Asian studies (eg, different sex distributions)
could explain this finding. Most of the other disease-associated
variants we found had slightly weaker effects in South Asians,
although, because power to detect heterogeneity of effect between
the ethnicities was low and there were only 2 South Asian studies,
this finding will require further evaluation. We observed variants
at 3 loci (TUB, LCT and MICB, Table S5) which showed modest
(P,10
24) associations in South Asians but were convincingly null
in Europeans and will therefore require replication in additional
South Asian samples. Overall, we did not find clear evidence of
major variation in genetic risk factors for CAD between
Europeans and South Asians.
In summary, using a large-scale gene-centric approach we have
identified novel associations of several genes for CAD that relate to
diverse biochemical and cellular functions, including inflammation
and novel lipid pathways, as well as genes of less certain function.
Together, these findings indicate that previously unsuspected
biological mechanisms operate in CAD, raising prospects for novel
approaches to intervention.
Materials and Methods
Participants
Characteristics of the discovery phase studies are summarised in
Table 1, Table S1 and the replication studies in Table S6. Further
details of all the studies are given in Text S1. All individuals
provided informed consent and all studies were approved by local
ethics committees.
Genotyping in discovery cohorts
Using the HumanCVD BeadChip array (Illumina), which is
also known as the ‘‘ITMAT-Broad-CARe’’ (IBC) 50K array, we
Table 1. Summary details of discovery and replication stage studies.
Stage Study Cases / Controls Male (%)
Mean age (SD) of
cases at diagnosis
Number of
cases with MI (%)
Version of
IBC array**
European discovery ARIC 424 / 8447 46.4 -u 368 (82.7) V2
BHF-FHS 2101 / 2426 63.3 49.8 (7.7) 1538 (73.2) V1
BLOODOMICS - Dutch 1462 / 1222 72.6 48.8 (12.0) 1462 (100) V2
BLOODOMICS - German 1910 / 1932 63.3 59.2 (10.9) 1181 (61.8) V2
CARDIA 87 / 1343 46.8 -u 86 (100) V2
CHS 737 / 3155 43.9 -u 381 (50.5) V2
FOS 59 / 6976 45.1 -u 13 (22.0) V2
MONICA-KORA 275 / 1413 57.5 52.9 (9.4) .50%* V1
PennCATH 1027 / 489 66.0 54.2 (8.8) 439 (40.6) V1
PROCARDIS 3120 / 3330 59.2 61.0 (8.7) 2136 (68.5) V2
Total 11,202 / 30,733
South Asian discovery PROMIS 1856 / 1905 82.5 53.3 (10.7) 1856 (100) V1
LOLIPOP 2538 / 2354 83.7 - 1125 (44.4) V2
Total 4394 / 4259
Replication CARDIoGRAM
{ 15,949 / 38,823 57.0 53.5 (9.8) 10,890 (68.3) N/A
EPIC-NL 1172 / 1650 30.6 51.9 (10.6) 341 (30.3) V3
Total 17,121 / 40,473
ARIC=Atherosclerosis Risk In Communities; BHF-FHS=British Heart Foundation Family Heart Study; CARDIA=Coronary Artery Risk Development in Young Adults;
CHS=Cardiovascular Health Study; FOS=Framingham Offspring Study; LOLIPOP=London Life Sciences Prospective Population Cohort; PROCARDIS=Precocious
Coronary Artery Disease; PROMIS=Pakistan Risk of Myocardial Infarction Study; EPIC-NL=European Prospective Investigation into Cancer & Nutrition (Netherlands)
cohort.
*All MONICA-KORA cases are either MI or sudden cardiac death.
**V2 contains an additional 132 genes (3,857 SNPs) compared to V1. SNPs on V2 were only analysed in studies that used the V2 array.
{Details of studies in the CARDIoGRAM Consortium are presented in Table S6.
uThe 4 studies in the CARe Consortium contributed data only on prevalent CAD cases at baseline for whom ages were not available.
doi:10.1371/journal.pgen.1002260.t001
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PLoS Genetics | www.plosgenetics.org 6 September 2011 | Volume 7 | Issue 9 | e1002260genotyped 49,094 single nucleotide polymorphisms (SNPs) in
,2,100 candidate genes identified in previous studies of cardiovas-
cular disease, pathway-based approaches (including genes related to
metabolism, lipids, thrombosis, circulation and inflammation), early
access to GWA datasets for CAD, type 2 diabetes, lipids and
hypertension, as well as human and mouse gene expression data
[10]. Variants in genes suspected to be associated with sleep, lung
and blood disease phenotypes were also included, along with SNPs
that were related in GWA datasets to rheumatoid arthritis, Crohn’s
disease and type 1 diabetes. Human and mouse gene expression
data was also used to select variants. Genes were then prioritised by
investigators, with ‘high priority genes’ densely tagged (all SNPs
with MAF.2% tagged at r
2.0.8), ‘intermediate priority genes’
moderately covered (all SNPs with MAF.5% tagged at r
2.0.5),
and ‘low priority genes’ tagged using only non-synonymous SNPs
and known functional variants with MAF.1%.
A ‘‘cosmopolitan tagging’’ approach was used to select SNPs
providing high coverage of selected genes in 4 HapMap popu-
lations (CEPH Caucasians, Han Chinese, Japanese, Yorubans).
For all genes, non-synonymous SNPs and known functional
variants were prioritised on the array. Genotypes were called using
standard algorithms (eg, GenCall Software and Illuminus) and
standard quality control methods were applied to filter out poorly
performing or rare (,1% minor allele frequency) SNPs (Text S1).
After exclusion of low frequency variants (average 8,354 in each
study), non-autosomal variants (average 1,224) and variants that
failed quality control (average 842 – predominantly due to high
missingness or failure of HWE), the number of SNPs taken forward
for analysis in each study ranged from 30,550–39,027 (Table S2).
Statistical analysis
In each study, unadjusted logistic regression tests using a case-
control design assuming an additive genetic model were
conducted, with most studies using PLINK [30]. All studies made
attempts to reduce over-dispersion. The genomic inflation factor
for each study after adjustment was ,1.10 with one exception
(Table S2). The primary analysis was a fixed-effect inverse-
variance-weighted meta-analysis performed separately for each
ethnic group using STATA v11. A chi-squared test for between-
ethnicity heterogeneity was performed. A secondary analysis
combined European and South Asian studies to identify additional
variants common to both ethnicities (Text S1).
Figure 3. Novel loci identified in the current study. Loci ordered by chromosomal position. SNP=SNP showing strongest evidence of
association in discovery stage studies; Frequency=pooled frequency of risk allele across controls; European discovery=per-allele odds ratio,
confidence interval and 2-tailed P value from fixed-effect meta-analysis of European discovery stage studies; South Asian discovery=per-allele odds
ratio, confidence interval and 2-tailed P value from fixed-effect meta-analysis of South Asian discovery stage studies; Combined discovery=per-allele
odds ratio, confidence interval and 2-tailed P value from fixed-effect meta-analysis of all European and South Asian discovery stage studies combined;
Replication=per-allele odds ratio, confidence interval and 1-tailed P value from fixed-effect meta-analysis of replication stage studies comprising
non-overlapping participants from CARDIoGRAM plus all participants from EPIC-NL; Overall=P value from relevant discovery stage studies combined
with the replication stage P value using Fisher’s method.
doi:10.1371/journal.pgen.1002260.g003
Figure 2. Manhattan plots for discovery stage meta-analyses. Y-axis shows unadjusted 2log10(P values) from fixed-effect meta-analysis of
discovery stage studies. NB: European and Combined plots are truncated at P=10
220. Blue horizontal line at P=10
24 indicates threshold for
replication; Red horizontal line at P=3610
26 indicates array-wide significance level.
doi:10.1371/journal.pgen.1002260.g002
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Based on a simulation study conducted prior to the analysis
(Figure S2), variants were selected for the replication stage if they
had an unadjusted P,1610
24 in either the primary analysis or
the combined ethnicity analysis. Only the most significant (‘‘lead’’)
SNP from each locus was taken forward for replication. SNPs at
known coronary disease risk loci (eg, 9p21.3, LPA, APOE) were
excluded from the replication stage, leaving 27 SNPs to take
forward. In silico replication was conducted using non-overlapping
participants from the CARDIoGRAM GWA meta-analysis [12] of
Figure 4. Regional association plots for novel loci identified. All SNPs included in meta-analysis of the European discovery stage studies are
represented by diamonds, with the lead SNP (lowest P value) at each locus represented by a large red diamond. Genes are represented as horizontal
arrows, with the direction of the arrow reflecting the direction of transcription. Recombination rates are represented as vertical blue peaks based on
the Hapmap 2 CEU population. P values are from fixed-effect meta-analysis. LD, represented as r
2, is estimated using the controls from the BHF-FHS
study, or Hapmap 2 CEU population where data were not available in BHF-FHS. Vertical dashed lines represent the extent of LD with the lead SNP,
based on an r
2 threshold of 0.5 in the Hapmap 2 CEU population. The genes between these lines represent the most likely candidate genes for each
association signal.
doi:10.1371/journal.pgen.1002260.g004
Figure 5. Effects of novel CAD loci on known cardiovascular risk factors. HDL-c=high-density lipoprotein cholesterol; LDL-c=low-density
lipoprotein cholesterol; Beta/odds ratio=combined effect from meta-analysis of SNP versus blood pressure/lipids/T2D. Results for lipids from meta-
analysis of 46 GWA studies containing up to 99,900 individuals [15]. Results for blood pressure from the Global BPGen Consortium: a meta-analysis of
17 GWA studies containing 25,870 individuals [14]. Results for diabetes from the DIAGRAM Consortium: a meta-analysis of 3 GWA studies containing
4,549 T2DM cases and 5,579 controls [13]. * No results available due to poor quality of SNP imputation.
doi:10.1371/journal.pgen.1002260.g005
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total, the replication stage comprised up to 17,121 coronary disease
cases and 40,473 controls. The threshold for indepen-
dent replication was a 1-tailed Bonferroni-corrected P,0.05
(P,1.9610
23) from a Cochran-Armitage trend test. P values from
the replication and discovery stages were combined using Fisher’s
method with a chip-wide value of P,3610
26 considered to be
statistically significant based on the simulation study (Figure S2).
Adjusted P values accounting for both over-dispersion and heteroge-
neity in the discovery stage studies were also estimated through
correction for study- and meta-analysis-specific inflation factors.
Additional analyses
To check for consistency of effect of variants that replicated,
subgroup analyses were performed in the discovery stage studies
for MI cases only, CAD cases aged less than 50, males only and
females only. Replicating SNPs were tested for association with
known cardiovascular risk factors such as blood pressure, lipids
levels and type 2 diabetes mellitus using existing large-scale GWA
meta-analyses data of these traits [13–15]. We also assessed the
association of these variants with gene expression in circulating
monocytes taken from 363 patients with premature myocardial
infarction and 395 healthy blood donors (Text S1). To put novel
findings from this study in the context of existing knowledge, we
summarised associations of common variants established in CAD
(P,5610
28) using available information from the NHGRI’s
GWA studies catalogue [32].
Supporting Information
Figure S1 Power to detect associated variants in discovery and
replication stages. Power to detect an association with al-
pha=10
24 (two-sided) assuming a per-allele effect and a discovery
stage study size of 11,202 coronary disease cases and 30,733
controls (equivalent to the European studies in the discovery stage)
across a range of minor allele frequencies (1%, 2%, 3%, 4%, 5%,
10%). These power calculations assume that there is no between-
study heterogeneity. Power to detect an association with
alpha=1.9610
23 (one-sided) assuming a per-allele effect and a
replication stage study size of 17,121 coronary disease cases and
40,473 controls (equivalent to the whole replication stage) range of
minor allele frequencies (5%, 10%, 25%, 50%). These power
calculations assume that there is no between-study heterogeneity.
(PDF)
Figure S2 Simulated distribution of P values from discovery
stage meta-analyses. The distribution of the number of SNPs with
a P value,10
24 under the null hypothesis of no associated SNPs
is based on 50,000 simulations using the controls from the BHF-
FHS study. The median is 2 significant SNPs (mean 2.5),
suggesting that using this threshold for taking SNPs to the
replication stage is likely to result in few false positives. The
comparable numbers for a threshold of P,10
23 are median=27
(mean 27), whilst the mean was 0.25 for P,10
25.T h e
distribution of lowest P value in each simulation across the
Human CVD Beadchip array is based on 50,000 simulations
Figure 6. Evidence for an eQTL association in the LIPA gene. Expression levels of LIPA in monocytes taken from 758 individuals assembled by
the Cardiogenics Consortium partitioned by genotype of SNP rs2246833. Boxes indicate interquartile ranges with a white horizontal line indicating
the median. Error bars represent absolute minimum and maximum levels with dots showing those levels considered to be outliers. rs2246833 is in
strong linkage disequilibrium (r
2=0.93; D9=1) with the CAD-associated variant at the LIPA locus (rs2246942). The T allele, which is associated with
increased LIPA expression, is inherited with the G allele of rs2246942, which is associated with increased risk of coronary disease.
doi:10.1371/journal.pgen.1002260.g006
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PLoS Genetics | www.plosgenetics.org 9 September 2011 | Volume 7 | Issue 9 | e1002260using the controls from the BHF-FHS study. The vertical line at
P=3 610
26 represents the 5th percentile, which was selected to
denote chip-wide significance.
(PDF)
Figure S3 Forest plots for novel SNPs in discovery stage studies.
Forest plots denote study-specific per-allele estimates of risk of
CAD, with the centre of each box representing the odds ratio, the
area of the box proportional to the weight (the inverse of the
variance), and the horizontal line indicating the 95% confidence
interval. Log odds ratios and standard errors were pooled using a
fixed-effect meta-analysis. Open diamonds represent pooled
estimates and 95% confidence intervals. European and South
Asian subgroup analyses did not differ significantly from each
other for any of the SNPs displayed.
(PDF)
Figure 7. Novel loci identified in this study placed in the context of previously confirmed CAD loci. Previously reported variants listed
are those from the NHGRI GWA studies catalogue [32] reported as having P,5610
28 with CAD. Per-allele odds ratios and percentage risk allele
frequencies (‘Freq’) are those listed in the catalogue. Frequencies and per-allele odds ratios for the novel variants reported in this study (appearing
below the dashed line) are from the CARDIoGRAM replication stage.
doi:10.1371/journal.pgen.1002260.g007
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discovery stage studies. Allele=Allele associated with increased
risk of CAD; Freq=frequency of risk allele in control populations.
MI=MI cases only vs all controls; Young=CAD cases diagnosed
aged less than 50 years.
(PDF)
Table S1 Details of studies included in the discovery stage.
- denotes ‘not applicable’ or ‘not available’. All values are means
(6SD) unless otherwise stated. Percentages may not be of all
available individuals due to missing data. ARIC=Atherosclerosis
Risk In Communities; BHF-FHS=British Heart Foundation
Family Heart Study; CARDIA=Coronary Artery Risk Develop-
ment in Young Adults; CHS=Cardiovascular Health Study;
FHS=Framingham Heart Study; LOLIPOP=London Life
Sciences Prospective Population Cohort; PROCARDIS=Preco-
cious Coronary Artery Disease; PROMIS=Pakistan Risk of
Myocardial Infarction Study. * age at baseline. 4 studies (BHF-
FHS, MONICA-KORA, PennCATH and PROMIS) used
version 1 (V1) of the array, whilst the other 8 used version 2
(V2). V2 contains an additional 132 genes (3,857 SNPs) hence
SNPs on V2 were only analysed in studies that used the V2 array.
Participants in the Framingham Heart Study were drawn from the
Offspring and Third Generation cohorts.
(PDF)
Table S2 Quality control information for SNPs in discovery
stage studies. Inflation factor=ratio of median observed chi
2 value
to that expected under the null hypothesis; MAF=minor allele
frequency; No result=no odds ratio obtained from model,
generally due to low MAF; HWE=Hardy-Weinberg equilibrium
(P value estimated for controls only).
(PDF)
Table S3 Results for all loci meeting P,10
23 in discovery stage
meta-analyses. SNPs are ordered by ascending P value in the
combined meta-analysis. Only the lead SNP (with the lowest P
value) from each locus is shown unless different SNPs met the
threshold in Europeans/South Asians. Data shown are per-allele
odds ratios from unadjusted fixed-effect inverse-variance meta-
analysis of 10 European studies, 2 South Asians studies and 12
studies combined. Loci highlighted in grey are those previously
identified by GWA studies; loci highlighted in yellow are
additional loci considered to be known CAD risk loci.
(PDF)
Table S4 Associations with previously studied candidate vari-
ants. Variants ordered by biological pathway, then gene. Per-allele
odds ratios are presented for the effect allele, which is the minor
allele in European populations. r
2 with best imputed proxy was
estimated using ,2.5 M directly genotyped or HapMap-imputed
SNPs in the CARDIoGRAM Consortium. Tagging levels are 1
(r
2.0.8 with all HapMap/Seattle SNPs of MAF$0.02), 2 (r
2.0.5
with all HapMap/Seattle SNPs of MAF$0.05), 3 (only non-
synonymous and known functional variants of MAF.0.01) and
GWAS (specific SNPs previously identified in recent GWAS).
a rs4343 has r
2=1 with the insertion/deletion polymorphism in
the ACE gene in CEU HapMap 2 population.
b rs17443251 has
r
2=0.75 with the more commonly studied R144C variant
(rs1799853) in the CYP2C9 gene in CEU HapMap 2 population.
c rs9526246 has r
2=0.97 with the more commonly studied T102C
variant (rs6313) in the HTR2A gene in CEU HapMap 2
population.
d rs1062535 has r
2=0.97 with the more commonly
studied C807T variant (rs1126643) in the ITGA2 gene in CEU
HapMap 2 population.
e rs1805096 has r
2=0.89 with the more
commonly studied rs6700896 variant in the LEPR gene in CEU
HapMap 2 population.
f rs1049897 has r
2=1 with the more
commonly studied A102T variant (rs4236) in the MGP gene in
CEU HapMap 2 population.
g rs4968624 has r
2=0.97 with the
more commonly studied L125V variant (rs668) in the PECAM1
gene in CEU HapMap 2 population.
h rs12944077 has r
2=1 with
the more commonly studied S563N variant (rs12953) in the
PECAM1 gene in CEU HapMap 2 population.
(PDF)
Table S5 27 loci meeting P,1610
24 threshold in discovery
stage meta-analyses. Lead SNP=SNP with lowest P-value at
this locus; risk allele=allele associated with increased CAD risk
according to forward strand; freq=frequency of risk allele
pooled across controls; OR=per-allele odds ratio for risk allele;
95% CI=95% confidence interval around odds ratio; P=P
value from fixed-effect meta-analysis; Combined=10 European
studies and 2 South Asian studies combined in a single fixed-
effect meta-analysis; Overall=P values from discovery stage and
replication stage combined; P_adj=P value adjusted for both
study-specific and meta-analysis inflation factors in the discov-
ery stage; SNPs ordered by ascending P value. * For 3 loci
(ZC3HC1, CYP17A1, COL4A1/COL4A2), replication data are
not presented here, however genome-wide significant associa-
tions at these loci are reported in the paper by the
CARDIoGRAM Consortium.
(PDF)
Table S6 Details of studies included in the replication stage. All
values are means (6SD) unless otherwise stated.
(PDF)
Table S7 Expression QTL (eQTL) analysis for novel CAD loci.
a. eQTL analysis for novel CAD loci. {Key (Proportion of
all Probes). 1=Weak (0%–20%). 2=Medium (20%–80%).
3=Strong (80%–100%). b. Conditional analysis of expression
QTL (eQTL) loci. Conditional analysis of the lead LIPA SNP on a
secondary SNP at the same locus that is also associated with gene
expression shows that the lead SNP at the LIPA locus has a strong
independent effect on LIPA expression levels. Conditional analysis
of the lead IL5 SNP on a second nearby SNP that is also associated
with RAD50 gene expression shows that the observed eQTL
association with the IL5 SNP is probably due to LD with the
RAD50 SNP.
(PDF)
Table S8 Comparison of haplotype frequencies for novel loci in
European and South Asian controls. Haplotypes are displayed in
decreasing frequency, with the same haplotype order in both
ethnicities. *=haplotype frequencies in bold are those containing
the CAD risk-associated allele of the lead SNP. SNPs were selected
for inclusion in the haplotype if they had r
2$0.5 in either the
European or the South Asian controls. The 3330 PROCARDIS
controls were used to represent the European populations, whilst
the PROMIS controls were used to represent the South Asian
population. Only haplotypes that were common (frequency.5%)
in at least one population are displayed.
(PDF)
Text S1 Supplementary Methods, Supplementary References,
Supplementary Acknowledgements.
(PDF)
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